Diagnostic Imaging's A Look Ahead: Dec. 14, 2020, to Dec. 20, 2020
Here's what to expect this week on Diagnostic Imaging.
In this week’s preview, here are some highlights of what you can expect to see coming soon on Diagnostic Imaging:
In continuing end-of-year coverage, keep an eye out for a look back at CT throughout 2020. What were the biggest developments and changes during the year. The biggest focus over the past nine months has certainly been with COVID-19, but what else happened with the modality as the pandemic raged?
For additional end-of-year coverage, click here.
For more coverage based on industry expert insights and research, subscribe to the Diagnostic Imaging e-Newsletter here.
RadXX announced their four award winners during RSNA – Trailblazer, Advocate, Rising Star, and Champion. Diagnostic Imaging spoke with each winner to find out not only what launched their interest in medical imaging informatics, but also what their visions were for the specialty going forward. Later this week, you can access a short video where they share their thoughts in their own words.
For more of the RadXX profiles, click here.
In the past 40 years, liver cancer diagnoses have tripled, and deaths have nearly doubled, making it a cancer to watch closely. Later this week, look for coverage of research that focuses on the use of ultrasound to impact liver tumors, potentially affecting overall treatment outcomes.
For additional liver cancer coverage, click here.
How to Successfully Launch a CCTA Program at Your Hospital or Practice
June 11th 2025Emphasizing increasing recognition of the capability of coronary computed tomography angiography (CCTA) for the evaluation of acute and stable chest pain, this author defuses common misperceptions and reviews key considerations for implementation of a CCTA program.
Possible Real-Time Adaptive Approach to Breast MRI Suggests ‘New Era’ of AI-Directed MRI
June 3rd 2025Assessing the simulated use of AI-generated suspicion scores for determining whether one should continue with full MRI or shift to an abbreviated MRI, the authors of a new study noted comparable sensitivity, specificity, and positive predictive value for biopsies between the MRI approaches.
Mammography AI Platform for Five-Year Breast Cancer Risk Prediction Gets FDA De Novo Authorization
June 2nd 2025Through AI recognition of subtle patterns in breast tissue on screening mammograms, the Clairity Breast software reportedly provides validated risk scoring for predicting one’s five-year risk of breast cancer.
